Low Health Literacy Prevalence's Study in Patients With Chronic Cardiovascular Disease

NCT ID: NCT03952013

Last Updated: 2022-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-19

Study Completion Date

2020-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Health literacy is the ability to access, understand, evaluate and apply information in order to communicate with health professionals and understand health instructions but also, promote, maintain and improve health throughout life. Health literacy (HL) is known as a health determinant.

An association has been shown between low HL and poorer health outcomes such as increased number of unscheduled hospitalisation or emergency visits, low medication adherence and poor health status.

These have been particularly demonstrated with cardiovascular diseases, which combine risk factors (emergency hospitalization, reduction in the length of hospital stays, and complex secondary preventive drug treatments). Despite large scientific international literature about HL and health outcomes, no information is available in France on the prevalence of low HL level among patients managed for neuro-cardio-vascular diseases.

It has been shown in other countries that healthcare professionals overestimate the HL level of their patients and do not adapt information to the HL level. Therefore, patients with low HL do not understand and/or are not able to use properly the information they receive.

Having a better knowledge of HL level and characteristics in these patients is necessary to develop tools for helping healthcare professionals to identify patients with low HL level and to realize the role of HL as a determinant of health. It will also provide more precise information on the difficulties or needs of patients with different levels of health literacy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

All eligible patients included into one of the three existing cohorts studies of Hospices Civils de Lyon's hospitals: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE

* LOOP-HF (Registry of Congestive Heart Failure, NCT03422991),
* HIBISCUS-STEMI (Prospective cohort with a heart attack from ST segment elevation myocardium admitted to the centre coronary angiography room participating investigators, NCT03070496)
* HIBISCUS-STROKE (Prospective cohort of Stroke patients, NCT03149705)

To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure

Intervention Type OTHER

All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure

All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Can be reached by phone (telephone numbers will be obtained through cohorts)
* Included in one of the 3 cohorts LOOP-HF (Heart Failure), HIBISCUS (stroke and myocardial infarction) with the following eligibility criteria:

LOOP-HF

* Patient with congestive heart failure confirmed after at the end of: Hospitalization for congestive cardiac decompensation, Follow-up for stable congestive heart failure in consultation with at least one episode of cardiac decompensation within the year
* NT-proBNP \> 500ng/l in the month before inclusion
* New York Heart Association (NYHA) ≥ 2
* Age \> 18 years old
* Signature informed consent

HIBISCUS-STROKE

* Age \> 18 years old
* Diagnosis of ischemic cerebral infarction confirmed by brain imaging
* Visible proximal occlusion on brain imaging (ACI or M1)
* Patient treated with thrombolysis and/or thrombectomy
* Signature of consent by the patient or family member

HIBISCUS-STEMI

* Age \> 18 years old
* STEMI diagnosis defined by an elevation of the ST segment ≥ 0.2 mV in 2 leads contiguous on a 12-lead ECG.
* Percutaneous coronary intervention (PCI)
* Obtaining informed and signed consent obtained or oral consent attested by a third party.

Exclusion Criteria

* Announcing an opposition to the study (an information letter will be sent to patients at home and their non-opposition to the study will be considered if the patient does not contact the coordination centre)
* Not speaking French

LOOP-HF

* Life expectancy \< 1 year
* Patient over 90 years of age
* Recent discovery of heart failure (\< 3 months) long-term assisted or cardiac transplant patient
* Inability to provide the patient with informed information
* Loss of autonomy, dementia, major dependence
* Lack of coverage by the social security system

HIBISCUS-STROKE

* Patients \> 50 km from Pierre Wertheimer Hospital (follow-up in Lyon impossible)
* Patient for whom H0 sampling is not possible (telemedicine)
* Patient with active or uncontrolled cancer.
* Stroke of unknown schedule
* Lack of coverage by a Social Security scheme
* Deprivation of civil rights (guardianship, guardianship, protection of justice)

HIBISCUS-STEMI

* Unconfirmed STEMI diagnosis in angiography
* Refusal to participate in the study or to sign the consent
* Inability to provide informed information about the subject
* Lack of coverage by a Social Security scheme
* Clear contraindication to magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, renal failure, known allergy to a product of contrast...)
* Deprivation of civil rights (guardianship, guardianship, protection of justice)
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LIT-S

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cardiovascular Health Study (CHS)
NCT00005133 ACTIVE_NOT_RECRUITING
Pawtucket Heart Health Program
NCT00005151 COMPLETED